Valeant Pharmaceuticals International (VRX) 31.09

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Valeant Pharmaceuticals International (VRX) 31.09 $VRX

Krispy Is Kremed; RIP Andy Grove; Biotechs in No-Man's Land: Jim Cramer's Best Blogs
at The Street - Fri Mar 25, 8:00PM CDT
Cramer dissects Krispy Kreme, honors a tech pioneer and laments the state of biotech stocks.
BIIB: 254.69 (-0.55), VRX: 31.09 (-2.34), WMT: 68.00 (+0.54), INTC: 31.88 (-0.12), SHLD: 15.00 (+0.04), AGN: 279.32 (-1.99), SBUX: 58.36 (-0.47), JACK: 63.12 (+0.02), JNJ: 108.31 (-0.19), DNKN: 45.32 (-0.21), IBM: 147.95 (+2.55), CMG: 471.37 (-3.09), ABBV: 56.12 (-0.24), SNY: 38.87 (-0.53), KKD: 14.61 (+0.32), REGN: 370.80 (+5.42), HD: 130.46 (+0.24), PFE: 30.08 (-0.11), LLY: 71.12 (-0.05), GSK: 39.56 (+0.19), BMY: 62.52 (+0.18), PLKI: 51.07 (+0.98), DIN: 92.00 (-1.02), CELG: 100.54 (+0.62), QSR: 37.63 (-0.38), GILD: 91.32 (+1.24), MRK: 53.07 (-0.01), AZN: 28.00 (-0.01), MCD: 123.29 (-0.90), WEN: 10.42 (+0.06)

A Scam Called Valeant
David Stockman - Daily Reckoning - Fri Mar 25, 3:28PM CDT
This post A Scam Called Valeant appeared first on Daily Reckoning . David Stockman shows you how financial justice has finally caught up with one of the darlings of “bubble finance”... The post A Scam Called Valeant appeared first on Daily...
VRX: 31.09 (-2.34)

Jim Cramer -- Biotech Stocks' Window of Opportunity
at The Street - Fri Mar 25, 1:30PM CDT
Jim Cramer says that biotech stocks could have a window of opportunity to rally as Valeant rebounds and as politicians lay off the sector.
VRX: 31.09 (-2.34), IBB: 255.48 (+1.22)

Valeant Pharmaceuticals Down 60%, but It's Still Not a Good Buy
Motley Fool Staff - Motley Fool - Fri Mar 25, 7:19AM CDT
Recently, Valeant Pharmaceuticals shares dropped 60% in a week after it announced on March 15 it would miss its annual report deadline -- and this was after the stock tanked by almost 90% in the past eight months. But even though a few notorious...
VRX: 31.09 (-2.34)

CEO of investment firm burned by Valeant stake is retiring
AP - Thu Mar 24, 6:21PM CDT
NEW YORK (AP) — The CEO of the investment firm with the largest stake in troubled Valeant Pharmaceuticals is retiring after the firm suffered punishing losses from its bets on the drug company.
VRX: 31.09 (-2.34), VRX.TO: 41.21 (-2.95)

If It Wasn't For Pfizer, Allergan Investors Might Be Getting Pummeled
Todd Campbell, The Motley Fool - Motley Fool - Thu Mar 24, 8:21AM CDT
SOURCE: FLICKR USER STOCKMONKEYS.COM The unraveling of its buy-reprice-relaunch strategy has led to shares in Valeant Pharmaceuticals  crumbling 80% in the past year, but Valeant Pharmaceuticals is far from the only publicly traded biopharma...
AGN: 279.32 (-1.99), VRX: 31.09 (-2.34), PFE: 30.08 (-0.11), HZNP: 16.02 (-0.30), TEVA: 54.29 (+0.24), DEPO: 13.31 (+0.17)

Valeant (VRX) Stock Climbs, Ackman Attempts to Reassure Investors
at The Street - Wed Mar 23, 12:16PM CDT
Valeant (VRX) stock is higher in afternoon trading on Wednesday as activist investor Bill Ackman explains to his own investors why he continues to believe in the company.
VRX: 31.09 (-2.34)

Trending Tickers: XOM, NKE, PBR, KKD, VRX
at The Street - Wed Mar 23, 12:04PM CDT
Oil prices continued to dictate market results on Wednesday as both the commodity and major indices declined. 
PBR: 5.40 (+0.04), VRX: 31.09 (-2.34), NKE: 61.65 (-0.79), XOM: 83.98 (+0.23)

Valeant Pharmaceuticals International Set to Possibly Pullback After Yesterday's Rally of 6.08%
Comtex SmarTrend(R) - Wed Mar 23, 11:58AM CDT
Valeant Pharmaceuticals International (NYSE:VRX) traded in a range yesterday that spanned from a low of $32.42 to a high of $34.40. Yesterday, the shares gained 6.1%, which took the trading range above the 3-day high of $32.05 on volume of 25.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRX: 31.09 (-2.34)

Valeant Vs. Sears: Will Bill Ackman Win This Time?
at The Street - Wed Mar 23, 11:29AM CDT
Bill Ackman's persistence to stay aboard a plunging Valeant hints at a lesson gleaned from his Sears investment years ago.
VRX: 31.09 (-2.34), SHLD: 15.00 (+0.04)

Is It Time to Buy Valeant Again?
at The Street - Wed Mar 23, 10:32AM CDT
Embattled Valeant Pharmaceuticals has enacted major management and operational changes. Will they be enough to turn around the scandal-plagued drug company?
VRX: 31.09 (-2.34)

Why Valeant Pharmaceuticals' Stock Rose 10% on Tuesday
George Budwell, The Motley Fool - Motley Fool - Wed Mar 23, 8:10AM CDT
Source: Flickr via user stockmonkeys.com. What's happening : Shares of Valeant Pharmaceuticals finally saw a green day yesterday, gaining 10% on extraordinary volume for the stock. The company's shares have been getting blasted during the last...
VRX: 31.09 (-2.34), HZNP: 16.02 (-0.30)

Cramer: Nike's Stock Might Rebound After the Easter Weekend
at The Street - Wed Mar 23, 5:30AM CDT
The stock may go the way of all quickly judged stocks in this market.
MNK: 60.06 (-0.38), VRX: 31.09 (-2.34), VAL: 105.88 (+0.88), NKE: 61.65 (-0.79), SHW: 281.35 (-1.64)

3 Beaten-Up Healthcare Stocks: Are They Bargains?
Todd Campbell, The Motley Fool - Motley Fool - Tue Mar 22, 9:26PM CDT
SOURCE: FLICKR USER ELLIOTT BROWN. A sharp sell-off in healthcare stocks has left many investors licking their wounds, but other investors might be licking their chops. With many healthcare stocks trading at their lowest valuation in years, the...
JNJ: 108.31 (-0.19), VRX: 31.09 (-2.34), AKRX: 24.37 (-0.40), DEPO: 13.31 (+0.17)

Stocks Run in Place as Brussels Attack Paralyzes Wall Street
at The Street - Tue Mar 22, 3:09PM CDT
A quieter holiday trading week was disrupted by tragedy on Tuesday, with dual explosions at a Brussels airport and metro station reigniting global concerns about terrorism.
VRX: 31.09 (-2.34), DAL: 47.84 (-1.07), PFE: 30.08 (-0.11), DB: 17.54 (-0.46), LL: 13.15 (+0.61), PCLN: 1,301.19 (-4.92), CELG: 100.54 (+0.62), UAL: 57.84 (-1.90), LUV: 44.06 (-0.37), GILD: 91.32 (+1.24), EXPE: 107.69 (-1.30), AAL: 40.50 (-1.42), AAPL: 105.67 (-0.46), IHG: 39.52 (+0.12)

Valeant Bids CEO Farewell, Embraces Ackman, and Shareholders Love It
at The Street - Tue Mar 22, 1:40PM CDT
Updated to reflect management pressure on boardmember Howard Shiller to step down, as the troubled drugmaker adds Bill Ackman to its board and CEO Michael Pearson steps down.
VRX: 31.09 (-2.34)

Options Play: Sell Valeant Puts
at The Street - Tue Mar 22, 1:02PM CDT
VRX put premiums are high, so use them to your advantage.
VRX: 31.09 (-2.34)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Valeant Pharmaceuticals International, Inc. -- VRX
Business Wire - Tue Mar 22, 12:48PM CDT
Levi & Korsinsky, LLP announces that it has commenced an investigation of Valeant Pharmaceuticals International, Inc. ("Valeant Pharmaceuticals" or the "Company" (NYSE:VRX) concerning possible violations of federal securities laws by certain officers and directors.
VRX: 31.09 (-2.34), VRX.TO: 41.21 (-2.95)

Trending Tickers: NKE, PBR, VRX, DKS
at The Street - Tue Mar 22, 12:10PM CDT
U.S. markets have been able to shake off investor fears following a terrorist attack in Belgium. 
PBR: 5.40 (+0.04), VRX: 31.09 (-2.34), NKE: 61.65 (-0.79), DKS: 46.71 (+0.08), MFRM: 39.30 (+0.09)

Jim Cramer -- Bernie Sanders Dropout Could Rally Biotech Stocks
at The Street - Tue Mar 22, 11:57AM CDT
If Hillary Clinton can knock Bernie Sanders from the Democratic presidential race, it could spur a rally in the biotech sector, says Jim Cramer.
VRX: 31.09 (-2.34), AMGN: 149.24 (+0.48), IBB: 255.48 (+1.22)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Regeneron Faces Class Action Over Tumultuous Trial Results

Updated Category News Views 3

Regeneron's Meltdown: A Bitter Pill for Investors Let’s dive headlong into the mess Regeneron Pharmaceuticals (NASDAQ:REGN) finds itself in—a classic nightmare scenario for investors. News broke like an old valve bursting, and suddenly, the market's love for Regeneron ran ice-cold. Who's to blame this time? Well, you might want to point a finger at the failed Phase 3...

Continue Reading
Big Wins at Americas Cardroom's $15M Venom Series

Updated Category News Views 0

High Stakes and Huge Paydays: The Venom Breakdown Alright, folks, here's a tale of how the cards fell in one of the most electrifying poker standoffs at Americas Cardroom. With prize pools clocking in at a staggering $15.095 million, the Dual Mystery Bounty Venoms really stacked the chips high. From the gritty, bustling halls of the internet to the proverbial green-felt...

Continue Reading
Drunk Angel Celebrates First Year in Crystal Jewelry

Updated Category News Views 2

One Year Down, A Unique Path Forward It's been a year since Drunk Angel jumped into the online jewelry scene, and they're setting themselves apart in their own glittery lane. Imagine starting a brand that's not just about pretty trinkets, but about linking those tiny treasures to timeless traditions. They've got their sights set on blending the deep tales of gemstones...

Continue Reading
Celebree Elevates Early Ed with New Certification Push

Updated Category News Views 0

A New Standard in Early Childhood Education In the cutthroat world of childcare and early education, just meeting the state standards ain't cutting it anymore. Celebree School, known for its infant, toddler, and preschool programs, is shaking things up with its 'Celebree Certified' initiative, setting a brand-new benchmark for teacher readiness that's far beyond the usual...

Continue Reading
Lida Group Expands Global Modular Construction Services

Updated Category News Views 5

Modular Construction's Expanding Footprint Behold Lida Group—a titan in the world of modular construction—taking ambitious strides into the global arena, reaching from the sand dunes of Saudi Arabia to the bustling corridors of the United Nations. If you haven't been paying attention, now's the time to get your head in the game. Their expansion isn't just about...

Continue Reading
Jollibee and DreamWorks Unite for Cultural Celebration

Updated Category News Views 1

Jollibee Partners with DreamWorks Animation Never thought I’d see the day: Jollibee, that familiar face of fast food, teaming up with the creative juggernaut DreamWorks Animation. They’re calling it a celebration of friendship and Filipino culture, wrapped up neatly in the context of a flick called Forgotten Island. Set to sizzle in theaters on September 25, 2026,...

Continue Reading
Dentsply Sirona Faces Insider Troubles: An Investor Call

Updated Category News Views 3

Are Dentsply Sirona Insiders on Thin Ice? The stock market's a tumultuous sea, and right now, it seems like some of those at the helm of Dentsply Sirona Inc. might be rocking the boat a bit too much. Let me tell you, navigating these corporate storms isn't for the faint-hearted. The latest noise coming from Halper Sadeh LLC suggests that some directors and officers over...

Continue Reading
DoorDash Speeds Up Gifting: Same-Day Delivery Wins

Updated Category News Views 3

Transforming Urgent Gift-Giving with Local Delivery Ever found yourself scrambling for a last-minute gift when time seems to be slipping away? That's where DoorDash steps up, changing the game with their same-day delivery options. In the fast-paced world we're living in, folks aren't just leaning on DoorDash for takeout anymore. They're pushing it as a lifeline for...

Continue Reading
Supernova SPAC Lawsuit: Settlement Proposed, $3M on Table

Updated Category News Views 3

Legal Clouds Over Supernova's SPAC Adventure Alright, folks, buckle up, because whenever you mix SPACs and lawsuits, you're in for a roller coaster. Supernova Partners Acquisition Company, Inc. stands right at the heart of a class action lawsuit, and it's been cooking ever since the court in Delaware gave it a nudge forward. Settlement Talk: What's on the Table? So here's...

Continue Reading
York Space Systems Faces Investor Lawsuit Over Claims

Updated Category News Views 1

Allegations Stir the Pot: York Space Systems Under Fire Now we're sailing into choppy waters with York Space Systems (YSS). There's a full-blown ruckus stirring as investors take aim at the company, thanks to a class action lawsuit alleging securities fraud. The legal beagles from Glancy Prongay Wolke & Rotter LLP are spearheading this effort, claiming that York pulled...

Continue Reading

Top 5 Most Recently Viewed Articles

Neumora Therapeutics: Upcoming Financial Results and Insights

Updated Category News Views 123

Neumora Therapeutics to Announce Financial Results Neumora Therapeutics, Inc. (Nasdaq: NMRA), a pioneering biopharmaceutical firm, is gearing up to share its financial outcomes for the second quarter of a future year. The conference call is set for 4:30 p.m. ET on a Wednesday, and this event aims to deliver important updates regarding their business and strategic...

Continue Reading
Exciting Insights into Claudin 6 Targeted Therapy for Cancer

Updated Category News Views 165

Introduction to TORL BioTherapeutics and TORL-1-23 TORL BioTherapeutics, LLC is leading the way in developing innovative cancer treatments, particularly focusing on antibody-drug conjugates that target Claudin 6. Their flagship product, TORL-1-23, has shown significant potential in recent clinical trials specifically aimed at patients with Claudin 6 positive cancers. This...

Continue Reading
Understanding Plasma Biomarkers for Liver Health in Youth

Updated Category News Views 118

Plasma Biomarkers and Liver Health in Adolescents Recent research has unveiled an exciting advancement in pediatric medicine regarding liver health in adolescents, particularly among Latino youth facing obesity. The study, conducted by the Children's Hospital Los Angeles, led by Principal Investigator Michael Goran, PhD, has explored the potential of plasma-based...

Continue Reading
Gruma's Market Control: A Look at Price Fixing in Mexico

Updated Category News Views 119

Cofece Ruling on Gruma's Price Fixing Authority In a significant decision that has set the stage for future pricing strategies, Mexico's antitrust authority, Cofece, announced that Gruma, a prominent player in the corn flour and tortilla market, has the ability to fix prices. This conclusion was reached following a comprehensive investigation, which revealed a lack of...

Continue Reading
Coloplast A/S Unveils Strong Financial Performance for 2024/25

Updated Category News Views 190

Coloplast A/S Interim Financial Highlights for 2024/25 Coloplast A/S has recently announced its interim financial results for the period from 1 October 2024 to 30 June 2025. This report unveils the company's impressive organic growth and highlights its strategies for maintaining its market position. Remarkable Growth Figures The latest results showcase an organic growth...

Continue Reading